Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Licenses Resolver to Aventis

NEW YORK, Dec. 11 - Rosetta Biosoftware said on Tuesday that   it has licensed its Rosetta Resolver gene-expression data-analysis system to Aventis Pharmaceuticals.


Financial or research specifics of the agreement were not revealed.


"The Rosetta Resolver system's ability to be networked into a multi-server global solution for our distributed enterprise was important to us," Christoph Brockel, head of Aventis Pharma's informatics group, said in a statement.


Rosetta Biosoftware is based in Kirkland, Wash., and Aventis Pharmaceuticals, of Cambridge, Mass., is the US business of German life sciences group Aventis Pharma.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.